Bulletin
Investor Alert

Alkermes PLC

NAS: ALKS

GO
/marketstate/country/us

After Hours

/zigman2/quotes/205084517/composite

$

21.71

Change

-0.48 -2.16%

Volume

Volume 22,871

Jan 22, 2021, 5:30 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/205084517/composite

Previous close

$ 21.47

$ 22.19

Change

+0.72 +3.35%

Day low

Day high

$21.15

$22.28

Open
Open: 21.17

52 week low

52 week high

$11.98

$23.02

Open

Market cap

$3.53B

Average volume

1.31M

P/E ratio

N/A

Rev. per Employee

$523,914

EPS

-0.46

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/alks

MarketWatch News on ALKS

  1. The Case for AbbVie as a Top Biopharma Stock in 2021

    8:45 a.m. Jan. 7, 2021

    - Barron's Online

  2. Alkermes upgraded to buy from neutral at Mizuho

    5:35 a.m. Oct. 15, 2020

    - Tomi Kilgore

  3. Alkermes stock price target raised to $24 from $19 at Mizuho

    5:04 a.m. Oct. 15, 2020

    - Tomi Kilgore

  4. Alkermes downgraded to neutral from buy at BofA Securities

    10:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  5. Alkermes stock price target cut to $20 from $31 at BofA Securities

    10:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  6. Alkermes downgraded to neutral from overweight at J.P. Morgan

    7:51 a.m. Feb. 14, 2020

    - Tomi Kilgore

  7. Alkermes stock price target cut to $21 from $25 at J.P. Morgan

    7:52 a.m. Feb. 14, 2020

    - Tomi Kilgore

  8. FDA told Alkermes to stop publishing Vivitrol ad

    12:12 p.m. Dec. 11, 2019

    - Jaimy Lee

  9. Alkermes to acquire Rodin Therapeutics for up to $950 million

    7:30 a.m. Nov. 18, 2019

    - Ciara Linnane

  10. Biogen shares fall 3%

    3:08 p.m. Nov. 14, 2019

    - Jaimy Lee

  11. Biogen, Alkermes MS treatment Vumerity gets FDA approval

    6:33 a.m. Oct. 30, 2019

    - Tomi Kilgore

  12. Alkermes upgraded to equal weight at Morgan Stanley

    9:09 a.m. Sept. 5, 2019

    - Tomi Kilgore

  13. Alkermes stock price target cut to $34 from $40 at Stifel Nicolaus

    7:55 a.m. Feb. 15, 2019

    - Tomi Kilgore

  14. Alkermes shares fall after FDA blocks antidepressant approval

    4:56 p.m. Feb. 1, 2019

    - Wallace Witkowski

  15. Alkermes reports positive results in late-stage trial of schizophrenia treatment

    7:01 a.m. Nov. 29, 2018

    - Ciara Linnane

  16. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/alks

Other News on ALKS

  1. Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA

    9:02 a.m. Jan. 22, 2021

    - Zacks.com

  2. AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer

    7:14 a.m. Jan. 21, 2021

    - Zacks.com

  3. Alkermes (ALKS) Gets a Hold Rating from J.P. Morgan

    4:06 a.m. Jan. 20, 2021

    - SmarterAnalyst

  4. Horizon (HZNP) Provides Preliminary 2020 Financial Results

    10:27 a.m. Jan. 12, 2021

    - Zacks.com

  5. NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session

    8:46 a.m. Jan. 11, 2021

    - Zacks.com

  6. Alkermes announces executive leadership team changes

    8:28 a.m. Jan. 6, 2021

    - Seeking Alpha

  7. Loading more headlines...
/news/pressrelease/company/us/alks

Press Releases on ALKS

  1. James Frates Joins Amylyx Pharmaceuticals as Chief Financial Officer

    8:00 a.m. Jan. 14, 2021

    - BusinessWire - BZX

  2. Loading more headlines...

Rates »

Link to MarketWatch's Slice.